Evolent Health (EVH) reported Q2 revenue of $653 million, up 31% sequentially, and adjusted EBITDA of $28 million, up 27%, supported by the May launch of its Highmark partnership and continued Performance Suite growth. The sequential operating momentum suggests improving profitability trends driven by partnership commercialization.
Evolent Health (EVH) reported Q2 revenue of $653 million, up 31% sequentially, and adjusted EBITDA of $28 million, up 27%, supported by the May launch of its Highmark partnership and continued Performance Suite growth. The sequential operating momentum suggests improving profitability trends driven by partnership commercialization.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
